Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | R289 |
Synonyms | |
Therapy Description |
R289 is a prodrug of R835, an inhibitor of IRAK1 and IRAK4, which potentially leads to decreased production of proinflammatory cytokines and immune cell-mediated cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
R289 | R906289 monosodium | IRAK1/4 Inhibitor 2 | R289 is a prodrug of R835, an inhibitor of IRAK1 and IRAK4, which potentially leads to decreased production of proinflammatory cytokines and immune cell-mediated cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05308264 | Phase Ib/II | R289 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Recruiting | USA | 0 |